Navafenterol, a new drug for the treatment of chronic obstructive airway disease
Y LIU, W WU, G WANG - Chinese Journal of Clinical …, 2024 - manu41.magtech.com.cn
Navafenterol is a new compound with both muscarinic receptor antagonist and β2 receptor
agonist effects in a single molecule, who is being developed for the treatment of chronic …
agonist effects in a single molecule, who is being developed for the treatment of chronic …
Navafenterol for chronic obstructive pulmonary disease therapy
Introduction Chronic obstructive pulmonary disease (COPD) is a prevalent disease of the
airways in which inhaled bronchodilators can be given as monotherapy or fixed dose …
airways in which inhaled bronchodilators can be given as monotherapy or fixed dose …
[PDF][PDF] Victor Balaguer1, Muna Albayaty2, Eulalia Jimenez3, Ulrika Wählby-Hamrén4, Carol Astbury1, Beatriz Seoane5
MP Malice, A Lei, A Aggarwal, I Psallidas - 2020 - respiratory-research.biomedcentral …
Abstract Background: Navafenterol (AZD8871) is a novel, long-acting, dual-pharmacology
(muscarinic receptor antagonist and β2− adrenoceptor agonist) molecule in development for …
(muscarinic receptor antagonist and β2− adrenoceptor agonist) molecule in development for …
Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual …
V Balaguer, M Albayaty, E Jimenez… - Respiratory …, 2020 - Springer
Background Navafenterol (AZD8871) is a novel, long-acting, dual-pharmacology
(muscarinic receptor antagonist and β 2− adrenoceptor agonist) molecule in development …
(muscarinic receptor antagonist and β 2− adrenoceptor agonist) molecule in development …
[PDF][PDF] Eulalia Jimenez1, Carol Astbury2, Muna Albayaty3, Ulrika Wählby-Hamrén4, Beatriz Seoane5, Cristina Villarroel6
H Pujol, MJ Bermejo, A Aggarwal, I Psallidas - 2020 - respiratory-research.biomedcentral …
Abstract Background: Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology
muscarinic antagonist/β2-adrenoceptor agonist (MABA) in development for the treatment of …
muscarinic antagonist/β2-adrenoceptor agonist (MABA) in development for the treatment of …
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
D Singh, J Beier, C Astbury, MG Belvisi… - European …, 2022 - Eur Respiratory Soc
Background Navafenterol (AZD8871) belongs to a new class of bronchodilator, the single-
molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD. This …
molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD. This …
Navafenterol. Dual M3 receptor antagonist/β2-adrenoceptor agonist (MABA), Treatment of chronic obstructive pulmonary disease
MG Matera, P Rogliani, M Cazzola - Drugs of the Future, 2022 - access.portico.org
There is evidence that dual bronchodilation is consistently more effective than long-acting
M3 muscarinic acetylcholine receptor (mAChR) antagonists (LAMAs) or long-acting β2 …
M3 muscarinic acetylcholine receptor (mAChR) antagonists (LAMAs) or long-acting β2 …
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel …
D Singh, V Balaguer, C Astbury, U Wählby-Hamrén… - Respiratory …, 2020 - Springer
Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β 2−
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and …
E Jimenez, C Astbury, M Albayaty… - Respiratory …, 2020 - Springer
Background Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology
muscarinic antagonist/β 2-adrenoceptor agonist (MABA) in development for the treatment of …
muscarinic antagonist/β 2-adrenoceptor agonist (MABA) in development for the treatment of …
Revefenacin for the treatment of chronic obstructive pulmonary disease
F Li, J Yang - Expert Review of Clinical Pharmacology, 2019 - Taylor & Francis
Introduction: Acetylcholine is the predominant parasympathetic neurotransmitter in the
airways, and plays a key role in the pathophysiology of chronic obstructive pulmonary …
airways, and plays a key role in the pathophysiology of chronic obstructive pulmonary …